FierceBiotechEditas, Adverum extend CRISPR ocular delivery allianceFierceBiotechEditas, Adverum extend CRISPR ocular delivery alliance. by Nick Paul Taylor |. Jan 26, 2018 9:10am. Editas allied with Adverum to expand the range of ocular targets it coul… Continue reading
Medical XpressFrom stem cells to a functional heart—the role of the Mesp1 geneMedical XpressResearchers at the Université libre de Bruxelles and University of Cambridge identified the role of key gene Mesp1 in the earliest step of cardiovascular lineag… Continue reading
|
CRISPR European patent cancellation highlights procedural IP pitfalls
IAM (blog) The European Patent Office’s revocation of a key patent relating to the revolutionary CRISPR technology sent shockwaves around the IP world last week. While the much-discussed ongoing US CRISPR dispute has raised fundamental questions about obviousness … The continuing CRISPR patent battle: the Broad Institute loses a key European patentLexology |
Courthouse News Service |
Stem–Cell Therapy: a Boon or a Boondoggle?
Courthouse News Service HOUSTON (CN) — Injected with 600 million stem cells grown from his own stomach fat, an elderly man said the injections stopped his Parkinson’s disease tremors and he’s now teeing up his own golf balls and competing in golf tournaments. A teenager said … |
PharmaTimes |
Scotland’s Synpromics expands gene therapy work with UCL deal
PharmaTimes Edinburgh, Scotland based Synpromics has teamed up with UCL Great Ormond Street Institute of Child Health to develop novel gene therapies for diseases affecting the haematopoietic system. This partnership further expands the firm’s activities in the … |
Zacks.com |
Novartis licenses ophthalmology gene therapy from Spark Therapeutics
Zenopa Novartis has agreed an exclusive licensing deal for an innovative ophthalmology gene therapy from Spark Therapeutics. The deal covers development, registration and commercialisation rights to voretigene neparvovec – which is sold in the US under the … Bio Roundup: Spark v. ICER, A Solid Revelation, T Cell Deals & MoreXconomy Novartis Gets Spark Therapeutics’ Luxterna License Outside USNasdaq |
|
What Good Is Crispr If It Can’t Get Where It Needs to Go?
WIRED The first US trials of Crispr safety are set to begin any day now, with Europe expected to follow later this year. Chinese scientists, meanwhile, have been testing Crispr humans since 2015, as the Wall Street Journal recently reported, with mixed … |